Key result
Persistent warfarin treatment reduced the risk of first ischaemic stroke compared to no persistent treatment in women (HR 0.25, CI 0.18-0.36) and men (HR 0.25, CI 0.19-0.32).
Why the study?
Does persistent warfarin treatment reduce the risk of first ischaemic stroke in primary care patients with atrial fibrillation?
Cohort (n=11,517)
Yes
Does persistent warfarin treatment reduce the risk of first ischaemic stroke in primary care patients with atrial fibrillation?
Hazard Ratio: 0.25
Persistent warfarin treatment significantly reduces the risk of first ischaemic stroke in primary care patients with atrial fibrillation without increasing the risk of haemorrhagic stroke.
Persistent warfarin was associated with lower ischaemic stroke risk in AF; leaves open need for randomized confirmation in contemporary cohorts.
Objective. Our aim was to study the risk of a first ischaemic stroke (IS) in patients with atrial fibrillation (AF) treated in primary healthcare. Design. The study population included all adults (n = 11,517), 45 years and older diagnosed with AF, from 75 primary care centres in Sweden between 2001 and 2007. IS was defined as a hospital care event of stroke between 2001 and 2010. Association between incident stroke and warfarin treatment was explored using Cox regression analysis, with hazard ratios (HRs), and 95% confidence intervals (95%CIs). Adjustment was made for age, socioeconomic factors and co-morbidity. Results. Persistent treatment with warfarin was present among 33.7% of women and 40.0% among men. Persistent warfarin treatment, compared to no persistent treatment, was associated with a stroke preventing effect with fully adjusted HRs of 0.25 (95%CI 0.18–0.36) in women, and 0.25 (95%CI 0.19–0.32) in men. A CHA2DS2-VASc score of at least two among women, and three among men, was associated with a stroke risk exceeding 18% during a mean follow-up of 5.4 years. Risk of haemorrhagic stroke was not increased. Conclusions. Warfarin is effective in preventing stroke in AF patients in primary healthcare.
No takes yet. Share an insight, caveat, or question.
Wändell et al. (2016) conducted a cohort in atrial fibrillation (n=11,517). Persistent warfarin treatment vs. No persistent treatment was evaluated on first ischaemic stroke (HR 0.25, 95% CI 0.18-0.36 (women), 0.19-0.32 (men)). Persistent warfarin treatment reduced the risk of first ischaemic stroke compared to no persistent treatment in women (HR 0.25, CI 0.18-0.36) and men (HR 0.25, CI 0.19-0.32).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: